Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 237 articles:
HTML format
Text format



Single Articles


    March 2017
  1. AFDHAL N, Everson GT, Calleja JL, McCaughan GW, et al
    Effect of Viral Suppression on Hepatic Venous Pressure Gradient in Hepatitis C With Cirrhosis and Portal Hypertension.
    J Viral Hepat. 2017 Mar 10. doi: 10.1111/jvh.12706.
    PubMed     Text format     Abstract available


  2. BUTI M, Dominguez-Hernandez R, Oyaguez I, Casado MA, et al
    Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12704.
    PubMed     Text format     Abstract available


  3. YOUNG K, Liu B, Bhuket T, Younossi Z, et al
    Long Term Trends in Chronic Hepatitis B Virus Infection Associated Liver Transplantation Outcomes in the United States.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12703.
    PubMed     Text format     Abstract available


  4. CHEW KW, Bhattacharya D, Horwich TB, Yan P, et al
    Performance of the Pooled Cohort Atherosclerotic Cardiovascular Disease Risk Score in Hepatitis C Virus-infected Persons.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12705.
    PubMed     Text format     Abstract available


  5. SHRIVASTAVA S, Wilson E, Poonia B, Tang L, et al
    Augmentation of HCV specific immunity and Sustained virological response (SVR).
    J Viral Hepat. 2017 Mar 7. doi: 10.1111/jvh.12702.
    PubMed     Text format     Abstract available


  6. CUNNINGHAM EB, Harjarizadeh B, Bretana NA, Amin J, et al
    Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study.
    J Viral Hepat. 2017 Mar 3. doi: 10.1111/jvh.12701.
    PubMed     Text format     Abstract available


  7. SMITH HL, Chung RT, Mantry P, Chapman W, et al
    Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    J Viral Hepat. 2017;24:197-206.
    PubMed     Text format     Abstract available


  8. TAIT JM, Wang H, Stephens BP, Miller M, et al
    Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.
    J Viral Hepat. 2017;24:207-215.
    PubMed     Text format     Abstract available


  9. AGUILERA A, Navarro D, Rodriguez Frias F, Viciana I, et al
    Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (The GEHEP 005 study).
    J Viral Hepat. 2017 Mar 1. doi: 10.1111/jvh.12700.
    PubMed     Text format     Abstract available


    February 2017
  10. ROMANI S, Hosseini SM, Mohebbi SR, Boonstra A, et al
    Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection.
    J Viral Hepat. 2017 Feb 20. doi: 10.1111/jvh.12699.
    PubMed     Text format     Abstract available


  11. DASHTSEREN B, Bungert A, Bat-Ulzii P, Enkhbat M, et al
    Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey among Mongolian adults.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12697.
    PubMed     Text format     Abstract available


  12. SHAKER OG, Senousy MA
    Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12696.
    PubMed     Text format     Abstract available


  13. DI BONA D, Aiello A, Colomba C, Bilancia M, et al
    KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12698.
    PubMed     Text format     Abstract available


  14. ZHANG W, Xie Q, Ning Q, Dou X, et al
    The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: a review of published literature.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12695.
    PubMed     Text format     Abstract available


  15. GRANNAN S
    Understanding Patient Perceptions and Risk for Hepatitis C Screening.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12692.
    PubMed     Text format     Abstract available


  16. YONGHAO G, Pumei D, Jianhui Y, Jin X, et al
    A retrospective study of hepatitis B mother-to-child transmission prevention and post-vaccination serological test results of infants at risk of perinatal transmission in two counties of middle China.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12694.
    PubMed     Text format     Abstract available


  17. TAMAKI N, Kurosaki M, Kusakabe A, Orito E, et al
    Hepatitis B Surface Antigen Reduction by Switching from Long-term Nucleoside/nucleotide Analog Administration to Pegylated Interferon.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12691.
    PubMed     Text format     Abstract available


  18. SOOMRO MH, Shi R, She R, Yang Y, et al
    Molecular and structural changes related to Hepatitis E virus (HEV) antigen and its expression in testis inducing apoptosis in Mongolian gerbil model.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12690.
    PubMed     Text format     Abstract available


  19. HSU HY, Chang MH, Ni YH, Chiang CL, et al
    Chronologic changes of serum hepatitis B virus DNA, genotypes, surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12687.
    PubMed     Text format     Abstract available


  20. MEIER MA, Suslov A, Ketterer S, Heim MH, et al
    Hepatitis B Virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12689.
    PubMed     Text format     Abstract available


  21. INGILIZ P
    Martinello et al.,HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2017 Feb 7. doi: 10.1111/jvh.12686.
    PubMed     Text format     Abstract available


  22. EL-AKEL W, El-Sayed MH, El Kassas M, El-Serafy M, et al
    National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.
    J Viral Hepat. 2017 Feb 1. doi: 10.1111/jvh.12668.
    PubMed     Text format     Abstract available


    January 2017
  23. ZHU MY, Zou X, Li Q, Yu DM, et al
    A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12682.
    PubMed     Text format     Abstract available


  24. HUNG CH, Wang JH, Lu SN, Hu TH, et al
    Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analog therapy.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12683.
    PubMed     Text format     Abstract available


  25. JANJUA NZ, Islam N, Wong J, Yoshida EM, et al
    Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12684.
    PubMed     Text format     Abstract available


  26. DIRKS M, Pflugrad H, Haag K, Tillmann HL, et al
    Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!
    J Viral Hepat. 2017 Jan 24. doi: 10.1111/jvh.12674.
    PubMed     Text format     Abstract available


  27. CHEN J, Xu CR, Xi M, Hu WW, et al
    Predictors of liver histological changes and a sustained response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12679.
    PubMed     Text format     Abstract available


  28. YU F, Zhou G, Huang K, Fan X, et al
    Serum lincRNA-p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12680.
    PubMed     Text format     Abstract available


  29. MENDIZABAL M, Reddy KR
    Chronic Hepatitis C and Chronic Kidney disease: Advances, Limitations and Unchartered Territories.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12681.
    PubMed     Text format     Abstract available


  30. FERNANDEZ-PONCE C, Munoz-Miranda JP, Arbulo-Echevarria MM, Litran R, et al
    Immune modulation by the Hepatitis C virus core protein.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12675.
    PubMed     Text format     Abstract available


  31. VEDIO A, Liu EZ, Lee AC, Salway S, et al
    Improving access to health care for chronic hepatitis B among migrant Chinese populations: a systematic mixed methods review of barriers and enablers.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12673.
    PubMed     Text format     Abstract available


  32. PLUMB ID, Bulkow LR, Bruce MG, Hennessy TW, et al
    Persistence of Antibody to Hepatitis A Virus 20 Years After Receipt of Hepatitis A Vaccine in Alaska.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12676.
    PubMed     Text format     Abstract available


  33. ZHOU S, Cella E, Zhou W, Kong WH, et al
    Population dynamics of HCV subtypes in injecting drug-users on methadone maintenance treatment in China associated with economic and health reform.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12677.
    PubMed     Text format     Abstract available


  34. LIU Z, Jiang L, Liang G, Song E, et al
    Hepatitis B Virus Reactivation in Breast Cancer Patients Undergoing Chemotherapy: a review and meta-analysis of prophylaxis management.
    J Viral Hepat. 2017 Jan 10. doi: 10.1111/jvh.12672.
    PubMed     Text format     Abstract available


    December 2016
  35. GOEL A, Sanchez J, Paulino L, Feuille C, et al
    A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12669.
    PubMed     Text format     Abstract available


  36. AYOUB H, Abu-Raddad LJ
    Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12671.
    PubMed     Text format     Abstract available


  37. MARTINELLO M, Grebely J, Petoumenos K, Gane E, et al
    HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2016 Dec 27. doi: 10.1111/jvh.12666.
    PubMed     Text format     Abstract available


  38. PAN CQ, Yi W, Liu M, Wan G, et al
    Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B.
    J Viral Hepat. 2016 Dec 26. doi: 10.1111/jvh.12640.
    PubMed     Text format     Abstract available


  39. THARINGER H, Rebbapragada I, Samuel D, Novikov N, et al
    Antibody-dependent and -independent uptake of HBsAg across human leukocyte subsets is similar between individuals with chronic hepatitis B Virus infection and healthy donors.
    J Viral Hepat. 2016 Dec 23. doi: 10.1111/jvh.12667.
    PubMed     Text format     Abstract available


  40. TOYODA H, Tada T, Takaguchi K, Senoh T, et al
    Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepa
    J Viral Hepat. 2016 Dec 16. doi: 10.1111/jvh.12665.
    PubMed     Text format     Abstract available


  41. PERELLO C, Carrion JA, Ruiz-Antoran B, Crespo J, et al
    Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12637.
    PubMed     Text format     Abstract available


  42. MUNOZ-GOMEZ R, Rincon D, Ahumada A, Hernandez E, et al
    Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12664.
    PubMed     Text format     Abstract available


  43. CONTI F, Brillanti S, Buonfiglioli F, Vukotic R, et al
    Safety and efficacy of direct acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12663.
    PubMed     Text format     Abstract available


  44. ELBASHA E, Greaves W, Roth D, Nwankwo C, et al
    Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    J Viral Hepat. 2016 Dec 13. doi: 10.1111/jvh.12639.
    PubMed     Text format     Abstract available


  45. XIONG H, Rong X, Wang M, Xu R, et al
    HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China.
    J Viral Hepat. 2016 Dec 12. doi: 10.1111/jvh.12644.
    PubMed     Text format     Abstract available


  46. ALONSO S, Riveiro-Barciela M, Fernandez I, Rincon D, et al
    Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12648.
    PubMed     Text format     Abstract available


  47. ALQAHTANI S, Ozaras R, Isakov V, Wyles D, et al
    Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12641.
    PubMed     Text format     Abstract available


  48. SHAH SR, Chowdhury A, Mehta R, Kapoor D, et al
    Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12654.
    PubMed     Text format     Abstract available


  49. DING Y, Duan S, Ye R, Yang Y, et al
    More Improvement than Progression of Liver Fibrosis Following Antiretroviral Therapy in A Longitudinal Cohort of HIV-infected Patients With or Without HBV and HCV Co-infections.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12658.
    PubMed     Text format     Abstract available


  50. GIMENO-BALLESTER V, Buti M, San Miguel R, Riveiro M, et al
    Interferon-free therapies for Patients with Chronic Hepatitis C Genotype 3 Infection: A Systematic Review.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12660.
    PubMed     Text format     Abstract available


  51. GITTO S, Gamal N, Andreone P
    NS5A inhibitors for the treatment of hepatitis C infection.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12657.
    PubMed     Text format     Abstract available


  52. WARING JF, Davis JW, Dumas E, Cohen D, et al
    Epigenetic analysis of the IFNlambda3 gene identifies a novel marker for response to therapy in HCV-infected subjects.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12661.
    PubMed     Text format     Abstract available


  53. CHANG LY, Li Y, Kaplan DE
    Hepatitis C viremia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B-cells.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12659.
    PubMed     Text format     Abstract available


  54. ALAEI A, Alaei K, Waye K, Tracy M, et al
    Hepatitis C Infection and Other Drug Related Harms Among Inpatients Who Injected Drugs in Turkey.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12662.
    PubMed     Text format     Abstract available


  55. DI BISCEGLIE AM, Lombardero M, Teckman J, Roberts L, et al
    Determination of hepatitis B phenotype using biochemical and serological markers.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12643.
    PubMed     Text format     Abstract available


  56. DURIER N, Yunihastuti E, Ruxrungtham K, Kinh NV, et al
    Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12630.
    PubMed     Text format     Abstract available


  57. KANAAN N, Raggi C, Goffin E, De Meyer M, et al
    Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12655.
    PubMed     Text format     Abstract available


  58. EMMANUEL B, Shardell MD, Tracy L, Kottilil S, et al
    Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12656.
    PubMed     Text format     Abstract available


  59. LLANERAS J, Riveiro-Barciela M, Buti M, Esteban R, et al
    Hepatitis C virus genotype 4: Genotype 1's little brother.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12620.
    PubMed     Text format     Abstract available


    November 2016
  60. LIU Y, Tang K, Long J, Zhao C, et al
    The association between hepatitis B self-awareness and depression: Exploring the modifying effects of socio-economic factors.
    J Viral Hepat. 2016 Nov 28. doi: 10.1111/jvh.12647.
    PubMed     Text format     Abstract available


  61. XU JH, Song LW, Li N, Wang S, et al
    Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir.
    J Viral Hepat. 2016 Nov 28. doi: 10.1111/jvh.12626.
    PubMed     Text format     Abstract available


  62. ISLAM N, Krajden M, Gilbert M, Gustafson P, et al
    Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12650.
    PubMed     Text format     Abstract available


  63. MCDONALD SA, Innes HA, Aspinall E, Hayes PC, et al
    Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12646.
    PubMed     Text format     Abstract available


  64. CHUAI X, Chen P, Chen H, Wang W, et al
    Protective efficacy and hepatitis B virus clearance in mice enhanced by cell-mediated immunity with novel prime-boost regimens.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12649.
    PubMed     Text format     Abstract available


  65. BARTLETT SR, Wertheim JO, Bull RA, Matthews GV, et al
    A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.
    J Viral Hepat. 2016 Nov 24. doi: 10.1111/jvh.12652.
    PubMed     Text format     Abstract available


  66. LAWITZ E, Poordad F, Gutierrez JA, Kakuda TN, et al
    Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    J Viral Hepat. 2016 Nov 23. doi: 10.1111/jvh.12645.
    PubMed     Text format     Abstract available


  67. JOO EJ, Chang Y, Yeom JS, Lee YG, et al
    Hepatitis B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis.
    J Viral Hepat. 2016 Nov 18. doi: 10.1111/jvh.12642.
    PubMed     Text format     Abstract available


  68. CHEN RC, Cai YJ, Wu JM, Wang XD, et al
    Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis.
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12638.
    PubMed     Text format     Abstract available


  69. BRUNO G, Saracino A, Fabrizio C, Scudeller L, et al
    Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A "turning-off" effect of liver inflammation?
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12636.
    PubMed     Text format    


  70. HEZODE C
    Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    J Viral Hepat. 2016 Nov 9. doi: 10.1111/jvh.12635.
    PubMed     Text format     Abstract available


  71. KHARABIAN MASOULEH S, Herzig S, Klose L, Roggenhofer E, et al
    Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study.
    J Viral Hepat. 2016 Nov 4. doi: 10.1111/jvh.12634.
    PubMed     Text format     Abstract available


  72. HUNDIE GB, Stalin Raj V, Gebre Michael D, Pas SD, et al
    A novel hepatitis B virus subgenotype D10 circulating in Ethiopia.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12631.
    PubMed     Text format     Abstract available


  73. RODRIGO C, Eltahla AA, Bull RA, Luciani F, et al
    Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12616.
    PubMed     Text format     Abstract available


  74. ITO H, Ando T, Nakamura M, Ishida H, et al
    Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12629.
    PubMed     Text format     Abstract available


  75. THOMPSON AJ, Bowden DS
    Vidal LL, et al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment-naive subjects. JVH, 2016, 23(11): 840-849.
    J Viral Hepat. 2016;23:838-839.
    PubMed     Text format    


    October 2016
  76. ESMAEILI A, Mirzazadeh A, Carter GM, Esmaeili A, et al
    Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.
    J Viral Hepat. 2016 Oct 28. doi: 10.1111/jvh.12628.
    PubMed     Text format     Abstract available


  77. EL RAZIKY M, Gamil M, Ashour MK, Sameea EA, et al
    Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naive and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
    J Viral Hepat. 2016 Oct 27. doi: 10.1111/jvh.12625.
    PubMed     Text format     Abstract available


  78. LAFFERTY L, Treloar C, Guthrie J, Chambers GM, et al
    Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
    J Viral Hepat. 2016 Oct 24. doi: 10.1111/jvh.12627.
    PubMed     Text format     Abstract available


  79. LEE S, Ahn SH, Jung KS, Kim DY, et al
    Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    J Viral Hepat. 2016 Oct 20. doi: 10.1111/jvh.12623.
    PubMed     Text format     Abstract available


  80. TAPPER EB, Bacon BR, Curry MP, Dieterich DT, et al
    Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    J Viral Hepat. 2016 Oct 11. doi: 10.1111/jvh.12611.
    PubMed     Text format     Abstract available


  81. CRISAN D, Radu C, Suciu A, Leach N, et al
    Hepatitis C in nonobese nondiabetic patients: Insulin resistance and the metabolic syndrome make a difference.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12610.
    PubMed     Text format    


  82. SCHEMMERER M, Rauh C, Jilg W, Wenzel JJ, et al
    Time course of hepatitis E-specific antibodies in adults.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12621.
    PubMed     Text format     Abstract available


  83. FEVERY B, Verbinnen T, Peeters M, Janssen K, et al
    Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    J Viral Hepat. 2016 Oct 3. doi: 10.1111/jvh.12614.
    PubMed     Text format     Abstract available


    September 2016
  84. SHI KQ, Zhou YY, Yan HD, Li H, et al
    Classification and regression tree analysis of acute-on-chronic hepatitis B liver failure: Seeing the forest for the trees.
    J Viral Hepat. 2016 Sep 30. doi: 10.1111/jvh.12617.
    PubMed     Text format     Abstract available


  85. WONG RJ, Nguyen MT, Trinh HN, Huynh A, et al
    Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
    J Viral Hepat. 2016 Sep 27. doi: 10.1111/jvh.12609.
    PubMed     Text format     Abstract available


  86. EMMANUEL B, Sidique N, Zhang X, Poonia B, et al
    Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12618.
    PubMed     Text format     Abstract available


  87. ELTAHLA AA, Rodrigo C, Betz-Stablein B, Grebely J, et al
    Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12615.
    PubMed     Text format     Abstract available


  88. LIU Y, Corsa AC, Buti M, Cathcart AL, et al
    No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    J Viral Hepat. 2016 Sep 23. doi: 10.1111/jvh.12613.
    PubMed     Text format     Abstract available


  89. TRIGO C, do Brasil PE, Costa MJ, de Castro L, et al
    Occult hepatitis B virus infection: clinical implications in tuberculosis treatment.
    J Viral Hepat. 2016 Sep 13. doi: 10.1111/jvh.12583.
    PubMed     Text format     Abstract available


  90. EL-BENDARY M, Neamatallah M, Esmat G, Kamel E, et al
    Associations of human leucocyte antigen class II-DQB1 alleles with hepatitis C virus infection in Egyptian population: a multicentre family-based study.
    J Viral Hepat. 2016 Sep 7. doi: 10.1111/jvh.12573.
    PubMed     Text format     Abstract available


    August 2016
  91. KEOSHKERIAN E, Hunter M, Cameron B, Nguyen N, et al
    Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection.
    J Viral Hepat. 2016 Aug 25. doi: 10.1111/jvh.12576.
    PubMed     Text format     Abstract available


  92. PRABDIAL-SING N, Chirwa T, Thaver J, Smuts H, et al
    Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008-2012.
    J Viral Hepat. 2016 Aug 21. doi: 10.1111/jvh.12571.
    PubMed     Text format     Abstract available


  93. ASPINALL EJ, Mitchell W, Schofield J, Cairns A, et al
    A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy.
    J Viral Hepat. 2016 Aug 11. doi: 10.1111/jvh.12580.
    PubMed     Text format     Abstract available


  94. ALLARD N, Dev A, Dwyer J, Srivatsa G, et al
    Factors associated with poor adherence to antiviral treatment for hepatitis B.
    J Viral Hepat. 2016 Aug 9. doi: 10.1111/jvh.12582.
    PubMed     Text format     Abstract available


  95. BRAHMANIA M, Brouwer WP, Hansen T, Mazzulli T, et al
    Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
    J Viral Hepat. 2016 Aug 9. doi: 10.1111/jvh.12579.
    PubMed     Text format     Abstract available


  96. KNOP V, Hoppe D, Welzel T, Vermehren J, et al
    Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.
    J Viral Hepat. 2016 Aug 8. doi: 10.1111/jvh.12578.
    PubMed     Text format     Abstract available


  97. BOYD A, Piroth L, Maylin S, Maynard-Muet M, et al
    Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
    J Viral Hepat. 2016 Aug 3. doi: 10.1111/jvh.12581.
    PubMed     Text format     Abstract available


    July 2016
  98. NISHIKAWA H, Enomoto H, Iwata Y, Kishino K, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.
    J Viral Hepat. 2016 Jul 31. doi: 10.1111/jvh.12575.
    PubMed     Text format     Abstract available


  99. CHEN X, Gui X, Zhang L, Huang F, et al
    Maternal anti-HBVs suppress the immune response of infants to hepatitis B vaccine.
    J Viral Hepat. 2016 Jul 29. doi: 10.1111/jvh.12572.
    PubMed     Text format     Abstract available


  100. WANG X, Gao F, Yuan G, Shi K, et al
    Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-alpha and ribavirin therapy.
    J Viral Hepat. 2016 Jul 24. doi: 10.1111/jvh.12574.
    PubMed     Text format     Abstract available


  101. SWANN RE, Mandalou P, Robinson MW, Ow MM, et al
    Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.
    J Viral Hepat. 2016 Jul 13. doi: 10.1111/jvh.12568.
    PubMed     Text format     Abstract available


  102. WILLEMSE SB, Baak LC, Kuiken SD, van der Sluys Veer A, et al
    Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
    J Viral Hepat. 2016 Jul 13. doi: 10.1111/jvh.12567.
    PubMed     Text format     Abstract available


  103. CHEN CM, Chen SC, Yang HY, Yang ST, et al
    Hospitalization and mortality due to hepatitis A in Taiwan: a 15-year nationwide cohort study.
    J Viral Hepat. 2016 Jul 7. doi: 10.1111/jvh.12564.
    PubMed     Text format     Abstract available


  104. MARTINOT-PEIGNOUX M, Lapalus M, Maylin S, Boyer N, et al
    Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
    J Viral Hepat. 2016 Jul 4. doi: 10.1111/jvh.12565.
    PubMed     Text format     Abstract available


    June 2016
  105. GHOSH S, Sow A, Guillot C, Jeng A, et al
    Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.
    J Viral Hepat. 2016 Jun 29. doi: 10.1111/jvh.12561.
    PubMed     Text format     Abstract available


  106. SCHEURICH C, Schulze Zur Wiesch J, Kim AY, Lewis-Ximenez L, et al
    Breadth of the HCV-specific CD4+ T-cell response in spontaneous resolvers is independent of the IL-28 haplotype.
    J Viral Hepat. 2016 Jun 27. doi: 10.1111/jvh.12560.
    PubMed     Text format    


  107. KAWAKAMI Y, Imamura M, Ikeda H, Suzuki M, et al
    Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.
    J Viral Hepat. 2016 Jun 27. doi: 10.1111/jvh.12553.
    PubMed     Text format     Abstract available


  108. FULOP B, Mihm U, Rohde P, Buggisch P, et al
    Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.
    J Viral Hepat. 2016 Jun 26. doi: 10.1111/jvh.12562.
    PubMed     Text format     Abstract available


  109. ZHOU YH
    Occult hepatitis B virus infection, or occult cross-contamination, in children of HBsAg-positive mothers.
    J Viral Hepat. 2016 Jun 23. doi: 10.1111/jvh.12559.
    PubMed     Text format    


  110. SHI R, Soomro MH, She R, Yang Y, et al
    Evidence of Hepatitis E virus breaking through the blood-brain barrier and replicating in the central nervous system.
    J Viral Hepat. 2016 Jun 21. doi: 10.1111/jvh.12557.
    PubMed     Text format     Abstract available


  111. YOUNOSSI ZM, Stepanova M, Sulkowski M, Naggie S, et al
    Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    J Viral Hepat. 2016 Jun 13. doi: 10.1111/jvh.12554.
    PubMed     Text format     Abstract available


  112. GANE E, Ben Ari Z, Mollison L, Zuckerman E, et al
    Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection.
    J Viral Hepat. 2016 Jun 12. doi: 10.1111/jvh.12552.
    PubMed     Text format     Abstract available


  113. JOO EJ, Yeom JS, Kwon MJ, Chang Y, et al
    Insulin resistance increases loss of antibody to hepatitis B surface antigen in nondiabetic healthy adults.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12556.
    PubMed     Text format     Abstract available


  114. DEBROY S, Hiraga N, Imamura M, Hayes CN, et al
    Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12551.
    PubMed     Text format     Abstract available


  115. GREBELY J, Litwin A, Dore GJ
    Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12550.
    PubMed     Text format    


    May 2016
  116. WEISSENBORN K, Tillmann HL
    HCV encephalopathy - an artefact due to medical care?
    J Viral Hepat. 2016 May 26. doi: 10.1111/jvh.12547.
    PubMed     Text format     Abstract available


  117. MIZOKAMI M, Dvory-Sobol H, Izumi N, Nishiguchi S, et al
    Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    J Viral Hepat. 2016 May 15. doi: 10.1111/jvh.12549.
    PubMed     Text format     Abstract available


  118. TESHALE EH, Xing J, Moorman A, Holmberg SD, et al
    Higher all-cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2013.
    J Viral Hepat. 2016 May 15. doi: 10.1111/jvh.12548.
    PubMed     Text format     Abstract available


  119. LOWRY D, Burke T, Galvin Z, Ryan JD, et al
    Is psychosocial and cognitive dysfunction misattributed to the virus in hepatitis C infection? Select psychosocial contributors identified.
    J Viral Hepat. 2016 May 11. doi: 10.1111/jvh.12544.
    PubMed     Text format     Abstract available


  120. LIM EJ, Chin R, Nachbur U, Silke J, et al
    Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents.
    J Viral Hepat. 2016 May 11. doi: 10.1111/jvh.12541.
    PubMed     Text format     Abstract available


  121. DEUFFIC-BURBAN S, Obach D, Canva V, Pol S, et al
    Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    J Viral Hepat. 2016 May 4. doi: 10.1111/jvh.12546.
    PubMed     Text format     Abstract available


    April 2016
  122. KATOONIZADEH A, Sharafkhah M, Ostovaneh MR, Norouzi A, et al
    Immune responses to hepatitis B immunization 10-18 years after primary vaccination: a population-based cohort study.
    J Viral Hepat. 2016 Apr 29. doi: 10.1111/jvh.12543.
    PubMed     Text format     Abstract available


  123. RAZAVI H
    Making the case for looking beyond WHO estimates for the global burden of hepatitis C and B.
    J Viral Hepat. 2016 Apr 5. doi: 10.1111/jvh.12539.
    PubMed     Text format     Abstract available


  124. EL-SERAG HB, Kramer J, Duan Z, Kanwal F, et al
    Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
    J Viral Hepat. 2016 Apr 3. doi: 10.1111/jvh.12533.
    PubMed     Text format     Abstract available


  125. PU Z, Li D, Wang A, Su H, et al
    Epidemiological characteristics of the carriers with coexistence of HBsAg and anti-HBs based on a community cohort study.
    J Viral Hepat. 2016;23:286-93.
    PubMed     Text format     Abstract available


  126. SADEGHI A, Yahyapour Y, Poortahmasebi V, Shahmoradi S, et al
    Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection.
    J Viral Hepat. 2016;23:282-5.
    PubMed     Text format     Abstract available


    March 2016
  127. LU M, Li J, Rupp LB, Holmberg SD, et al
    Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma.
    J Viral Hepat. 2016 Mar 30. doi: 10.1111/jvh.12538.
    PubMed     Text format     Abstract available


  128. BASNAYAKE SK, Easterbrook PJ
    Wide variation in estimates of global prevalence and burden and death estimates from chronic HBV, HCV and coinfection with HIV in literature.
    J Viral Hepat. 2016 Mar 30. doi: 10.1111/jvh.12519.
    PubMed     Text format     Abstract available


  129. HARRIS RJ, Martin NK, Rand E, Mandal S, et al
    New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.
    J Viral Hepat. 2016 Mar 29. doi: 10.1111/jvh.12529.
    PubMed     Text format     Abstract available


  130. BUNCHORNTAVAKUL C, Reddy KR
    Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.
    J Viral Hepat. 2016 Mar 28. doi: 10.1111/jvh.12534.
    PubMed     Text format     Abstract available


  131. GIUDICI F, Bertisch B, Negro F, Stirnimann G, et al
    Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12535.
    PubMed     Text format     Abstract available


  132. REN JP, Ying RS, Cheng YQ, Wang L, et al
    HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12537.
    PubMed     Text format     Abstract available


  133. MO H, Hedskog C, Svarovskaia E, Sun SC, et al
    Antiviral response and resistance analysis of treatment-naive HCV-infected patients receiving single and multiple doses of GS-9190.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12536.
    PubMed     Text format     Abstract available


  134. GRAY E, O'Leary A, Kieran JA, Fogarty E, et al
    Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
    J Viral Hepat. 2016 Mar 21. doi: 10.1111/jvh.12532.
    PubMed     Text format     Abstract available


  135. SERVANT-DELMAS A, Abravanel F, Lefrere JJ, Lionnet F, et al
    New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France.
    J Viral Hepat. 2016 Mar 18. doi: 10.1111/jvh.12531.
    PubMed     Text format     Abstract available


  136. PERUMALSWAMI PV, Patel N, Bichoupan K, Ku L, et al
    High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens.
    J Viral Hepat. 2016 Mar 17. doi: 10.1111/jvh.12530.
    PubMed     Text format     Abstract available


  137. YOUNOSSI ZM, Stepanova M, Henry L, Younossi I, et al
    Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.
    J Viral Hepat. 2016 Mar 14. doi: 10.1111/jvh.12528.
    PubMed     Text format     Abstract available


  138. RODRIGUEZ-TORRES M, Glass S, Hill J, Freilich B, et al
    GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
    J Viral Hepat. 2016 Mar 9. doi: 10.1111/jvh.12527.
    PubMed     Text format     Abstract available


  139. ROQUE CUELLAR MC, Garcia-Lozano JR, Sanchez B, Praena-Fernandez JM, et al
    Lymphomagenesis-related gene expression in B cells from sustained virological responders with occult hepatitis C virus infection.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12526.
    PubMed     Text format     Abstract available


  140. STELMA F, Jansen L, Sinnige MJ, van Dort KA, et al
    HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12525.
    PubMed     Text format     Abstract available


  141. RAJBHANDARI R, Barton K, Juncadella AC, Rubin AK, et al
    Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12524.
    PubMed     Text format     Abstract available


  142. ZAYED N, Gamal Eldeen H, Elmakhzangy H, Seif M, et al
    Therapeutic outcome of 6198 interferon-naive Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era.
    J Viral Hepat. 2016 Mar 3. doi: 10.1111/jvh.12514.
    PubMed     Text format     Abstract available


  143. VISVANATHAN K, Lang T, Ryan K, Wilson R, et al
    Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.
    J Viral Hepat. 2016;23:170-9.
    PubMed     Text format     Abstract available


    February 2016
  144. NINOMIYA M, Kondo Y, Kimura O, Funayama R, et al
    The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12522.
    PubMed     Text format     Abstract available


  145. PEVELING-OBERHAG J, Arcaini L, Bankov K, Zeuzem S, et al
    The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12518.
    PubMed     Text format     Abstract available


  146. WOODE ME, Abu-Zaineh M, Perriens J, Renaud F, et al
    Potential market size and impact of hepatitis C treatment in low- and middle-income countries.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12516.
    PubMed     Text format     Abstract available


  147. HARRIS M, Ward E, Gore C
    Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12513.
    PubMed     Text format     Abstract available


  148. CHEN HH, Liu PF, Tsai HH, Yen RF, et al
    Re: Wangensteen et al. of a letter on 'Hepatitis C virus infection: a risk factor for Parkinson's disease.'
    J Viral Hepat. 2016 Feb 23. doi: 10.1111/jvh.12521.
    PubMed     Text format    


  149. WANGENSTEEN KJ, Krawitt EL, Hamill RW, Boyd JT, et al
    Hepatitis C virus infection: a risk factor for Parkinson's disease.
    J Viral Hepat. 2016 Feb 23. doi: 10.1111/jvh.12517.
    PubMed     Text format    


  150. SCHNIER C, Wild S, Kurdi Z, Povey C, et al
    Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection.
    J Viral Hepat. 2016 Feb 22. doi: 10.1111/jvh.12520.
    PubMed     Text format     Abstract available


  151. KONERMAN MA, Brown M, Zheng Y, Lok AS, et al
    Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data.
    J Viral Hepat. 2016 Feb 19. doi: 10.1111/jvh.12509.
    PubMed     Text format     Abstract available


  152. DRAVE SA, Debing Y, Walter S, Todt D, et al
    Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells.
    J Viral Hepat. 2016 Feb 19. doi: 10.1111/jvh.12515.
    PubMed     Text format     Abstract available


  153. AHN SH, Lim YS, Lee KS, Paik SW, et al
    A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
    J Viral Hepat. 2016 Feb 10. doi: 10.1111/jvh.12499.
    PubMed     Text format     Abstract available


  154. HAWKS L, Norton BL, Cunningham CO, Fox AD, et al
    The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic.
    J Viral Hepat. 2016 Feb 9. doi: 10.1111/jvh.12512.
    PubMed     Text format     Abstract available


  155. GISA A, Suneetha PV, Behrendt P, Pischke S, et al
    Cross-specific T-cell responses in acute hepatitis E virus (HEV) infection.
    J Viral Hepat. 2016 Feb 8. doi: 10.1111/jvh.12495.
    PubMed     Text format     Abstract available


  156. MEISSNER EG, Kohli A, Virtaneva K, Sturdevant D, et al
    Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12510.
    PubMed     Text format     Abstract available


  157. FALADE-NWULIA O, Mehta SH, Lasola J, Latkin C, et al
    Public health clinic-based hepatitis C testing and linkage to care in baltimore.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12507.
    PubMed     Text format     Abstract available


  158. YOUNOSSI ZM, Bacon BR, Dieterich DT, Flamm SL, et al
    Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12506.
    PubMed     Text format     Abstract available


  159. BOGLIONE L, Cariti G, Di Perri G, D'Avolio A, et al
    Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all?
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12502.
    PubMed     Text format    


  160. PAPATHEODORIDIS G, Thomas HC, Golna C, Bernardi M, et al
    Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.
    J Viral Hepat. 2016;23 Suppl 1:1-12.
    PubMed     Text format     Abstract available


  161. MINA MM, Cameron B, Luciani F, Vollmer-Conna U, et al
    Natural killer cells in highly exposed hepatitis C-seronegative injecting drug users.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12511.
    PubMed     Text format     Abstract available


  162. BROERING R, Trippler M, Werner M, Real CI, et al
    Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12508.
    PubMed     Text format     Abstract available


  163. POITEAU L, Soulier A, Rosa I, Roudot-Thoraval F, et al
    Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12501.
    PubMed     Text format     Abstract available


  164. IDRISSI ME, Hachem H, Koering C, Merle P, et al
    HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype.
    J Viral Hepat. 2016;23:130-8.
    PubMed     Text format     Abstract available


    January 2016
  165. STUBBS A, Naylor P, Ravindran K, Benjaram S, et al
    Racial diversity in mortality and morbidity in urban patients with hepatitis C.
    J Viral Hepat. 2016 Jan 28. doi: 10.1111/jvh.12504.
    PubMed     Text format     Abstract available


  166. VIDAL LL, Soares MA, Santos AF
    NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naive subjects.
    J Viral Hepat. 2016 Jan 18. doi: 10.1111/jvh.12503.
    PubMed     Text format     Abstract available


  167. PFLUGRAD H, Meyer GJ, Dirks M, Raab P, et al
    Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction.
    J Viral Hepat. 2016 Jan 15. doi: 10.1111/jvh.12496.
    PubMed     Text format     Abstract available


  168. ORTEGA-PRIETO AM, Dorner M
    The expanding toolbox for hepatitis C virus research.
    J Viral Hepat. 2016 Jan 13. doi: 10.1111/jvh.12500.
    PubMed     Text format     Abstract available


  169. SHRESTHA A, Lama TK, Gupta BP, Sapkota B, et al
    Hepatitis E virus outbreak in postearthquake Nepal: is a vaccine really needed?
    J Viral Hepat. 2016 Jan 12. doi: 10.1111/jvh.12505.
    PubMed     Text format    


  170. VELAY A, Jeulin H, Eschlimann M, Malve B, et al
    Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.
    J Viral Hepat. 2016 Jan 6. doi: 10.1111/jvh.12498.
    PubMed     Text format     Abstract available


  171. FOSTER GR
    The Journal Of Viral Hepatitis 2016.
    J Viral Hepat. 2016;23:4.
    PubMed     Text format    


    December 2015
  172. DUARTE-ROJO A, Fischer SE, Adeyi O, Zita D, et al
    Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
    J Viral Hepat. 2015 Dec 29. doi: 10.1111/jvh.12494.
    PubMed     Text format     Abstract available


  173. ZHANG S, Ma Q, Liang S, Xiao H, et al
    Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China.
    J Viral Hepat. 2015 Dec 10. doi: 10.1111/jvh.12482.
    PubMed     Text format     Abstract available


  174. BURCHILL MA, Golden-Mason L, Wind-Rotolo M, Rosen HR, et al
    Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
    J Viral Hepat. 2015;22:983-91.
    PubMed     Text format     Abstract available


  175. ALFALEH FZ, Nugrahini N, Maticic M, Tolmane I, et al
    Strategies to manage hepatitis C virus infection disease burden - volume 3.
    J Viral Hepat. 2015;22 Suppl 4:42-65.
    PubMed     Text format     Abstract available


  176. SIBLEY A, Han KH, Abourached A, Lesmana LA, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.
    J Viral Hepat. 2015;22 Suppl 4:21-41.
    PubMed     Text format     Abstract available


  177. LIAKINA V, Hamid S, Tanaka J, Olafsson S, et al
    Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.
    J Viral Hepat. 2015;22 Suppl 4:4-20.
    PubMed     Text format     Abstract available


  178. AGHEMO A, Dore GJ, Hatzakis A, Wedemeyer H, et al
    Estimating HCV disease burden - volume 3 (editorial).
    J Viral Hepat. 2015;22 Suppl 4:1-3.
    PubMed     Text format    


  179. ZHOU X, Xu L, Wang W, Watashi K, et al
    Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.
    J Viral Hepat. 2015 Dec 1. doi: 10.1111/jvh.12491.
    PubMed     Text format     Abstract available


    November 2015
  180. YOUNG KL, Huang W, Horsburgh CR, Linas BP, et al
    Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission.
    J Viral Hepat. 2015 Nov 17. doi: 10.1111/jvh.12489.
    PubMed     Text format     Abstract available


  181. FOSTER GR, Ferenci P, Asselah T, Mantry P, et al
    Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
    J Viral Hepat. 2015 Nov 17. doi: 10.1111/jvh.12485.
    PubMed     Text format     Abstract available


  182. DULTZ G, Gerber L, Zeuzem S, Sarrazin C, et al
    The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.
    J Viral Hepat. 2015 Nov 10. doi: 10.1111/jvh.12488.
    PubMed     Text format     Abstract available


  183. GONZALES CA, Bacchetti P, Khalili M
    Impact of gender and menopausal status on metabolic parameters in chronic hepatitis C infection.
    J Viral Hepat. 2015 Nov 10. doi: 10.1111/jvh.12487.
    PubMed     Text format     Abstract available


  184. CHANG ML, Huang YH, Cheng JC, Yeh CT, et al
    Interaction between hepatic membrane type 1 matrix metalloproteinase and acireductone dioxygenase 1 regulates hepatitis C virus infection.
    J Viral Hepat. 2015 Nov 5. doi: 10.1111/jvh.12486.
    PubMed     Text format     Abstract available


    October 2015
  185. PADAM P, Clark S, Irving W, Gellissen R, et al
    Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease.
    J Viral Hepat. 2015 Oct 29. doi: 10.1111/jvh.12484.
    PubMed     Text format     Abstract available


  186. YOUNOSSI Z, Brown A, Buti M, Faiguoli S, et al
    Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
    J Viral Hepat. 2015 Oct 20. doi: 10.1111/jvh.12483.
    PubMed     Text format     Abstract available


  187. RIOU J, Ait Ahmed M, Blake A, Vozlinsky S, et al
    Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis.
    J Viral Hepat. 2015 Oct 19. doi: 10.1111/jvh.12481.
    PubMed     Text format     Abstract available


  188. RAJALAKSHMY AR, Malathi J, Madhavan HN
    Serum-derived hepatitis C virus 1a infection of human astrocyte cell line SVG.
    J Viral Hepat. 2015 Oct 15. doi: 10.1111/jvh.12480.
    PubMed     Text format     Abstract available


  189. VAN DE KLUNDERT MA, Zaaijer HL, Kootstra NA
    Identification of FDA-approved drugs that target hepatitis B virus transcription.
    J Viral Hepat. 2015 Oct 12. doi: 10.1111/jvh.12479.
    PubMed     Text format     Abstract available


  190. CROSSAN C, Tsochatzis EA, Longworth L, Gurusamy K, et al
    Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation.
    J Viral Hepat. 2015 Oct 7. doi: 10.1111/jvh.12469.
    PubMed     Text format     Abstract available


  191. WARING JF, Dumas EO, Abel S, Coakley E, et al
    Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.
    J Viral Hepat. 2015 Oct 5. doi: 10.1111/jvh.12470.
    PubMed     Text format     Abstract available


    September 2015
  192. STAHMEYER JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, et al
    Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
    J Viral Hepat. 2015 Sep 28. doi: 10.1111/jvh.12471.
    PubMed     Text format     Abstract available


  193. BROUWER WP, Sonneveld MJ, Xie Q, Guo S, et al
    Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients.
    J Viral Hepat. 2015 Sep 25. doi: 10.1111/jvh.12468.
    PubMed     Text format     Abstract available


  194. FAN YC, Sun YY, Wang N, Xiao XY, et al
    Up-regulation of A20 gene expression in peripheral blood mononuclear cells is associated with acute-on-chronic hepatitis B liver failure.
    J Viral Hepat. 2015 Sep 24. doi: 10.1111/jvh.12478.
    PubMed     Text format     Abstract available


  195. CARMO RF, Aroucha D, Vasconcelos LR, Pereira LM, et al
    Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV.
    J Viral Hepat. 2015 Sep 24. doi: 10.1111/jvh.12472.
    PubMed     Text format     Abstract available


  196. FERNANDEZ-MONTERO JV, Barreiro P, de Mendoza C, Labarga P, et al
    Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients.
    J Viral Hepat. 2015 Sep 21. doi: 10.1111/jvh.12447.
    PubMed     Text format     Abstract available


  197. TANGKIJVANICH P, Chittmittraprap S, Poovorawan K, Limothai U, et al
    A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.
    J Viral Hepat. 2015 Sep 21. doi: 10.1111/jvh.12467.
    PubMed     Text format     Abstract available


  198. LAGGING M, Brown A, Mantry PS, Ramji A, et al
    Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
    J Viral Hepat. 2015 Sep 10. doi: 10.1111/jvh.12464.
    PubMed     Text format     Abstract available


  199. KHUROO MS, Khuroo MS
    Hepatitis E: an emerging global disease - from discovery towards control and cure.
    J Viral Hepat. 2015 Sep 6. doi: 10.1111/jvh.12445.
    PubMed     Text format     Abstract available



  200. The Viral Hepatitis Congress 2015, Kap Europa, Frankfurt, Germany.
    J Viral Hepat. 2015;22 Suppl 3:1-49.
    PubMed     Text format    


    August 2015
  201. WOZNIAK MA, Lugo Iparraguirre LM, Dirks M, Deb-Chatterji M, et al
    Apolipoprotein E-epsilon4 deficiency and cognitive function in hepatitis C virus-infected patients.
    J Viral Hepat. 2015 Aug 26. doi: 10.1111/jvh.12443.
    PubMed     Text format     Abstract available


  202. TRELOAR C, Rance J, Bryant J, Fraser S, et al
    Understanding decisions made about hepatitis C treatment by couples who inject drugs.
    J Viral Hepat. 2015 Aug 25. doi: 10.1111/jvh.12451.
    PubMed     Text format     Abstract available


  203. YOUNOSSI ZM, Stepanova M, Saab S, Ahmed A, et al
    The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.
    J Viral Hepat. 2015 Aug 20. doi: 10.1111/jvh.12449.
    PubMed     Text format     Abstract available


  204. YIN P, Zhang L
    Aspirin inhibits hepatitis C virus entry by downregulating claudin-1.
    J Viral Hepat. 2015 Aug 20. doi: 10.1111/jvh.12446.
    PubMed     Text format     Abstract available


  205. YOUNOSSI ZM, Elsheikh E, Stepanova M, Gerber L, et al
    Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
    J Viral Hepat. 2015 Aug 17. doi: 10.1111/jvh.12448.
    PubMed     Text format     Abstract available


  206. SUK-FONG LOK A
    Hepatitis B: 50 years after the discovery of Australia antigen.
    J Viral Hepat. 2015 Aug 17. doi: 10.1111/jvh.12444.
    PubMed     Text format     Abstract available


  207. PHO MT, Jensen DM, Meltzer DO, Kim AY, et al
    Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
    J Viral Hepat. 2015;22:630-638.
    PubMed     Text format     Abstract available


  208. CRAXI L, Camma C, Craxi A
    HCV: the best cure possible or the best possible cure?
    J Viral Hepat. 2015;22:627-629.
    PubMed     Text format     Abstract available


  209. ATHANASAKIS K, Petrakis I, Kyriopoulos J
    'HepConomics': cost-effective, indeed, but how can we pay for it?
    J Viral Hepat. 2015;22:682.
    PubMed     Text format    


    July 2015
  210. REN F, Shi H, Zhang L, Zhang X, et al
    The dysregulation of endoplasmic reticulum stress response in acute-on-chronic liver failure patients caused by acute exacerbation of chronic hepatitis B.
    J Viral Hepat. 2015 Jul 31. doi: 10.1111/jvh.12438.
    PubMed     Text format     Abstract available


  211. SAMADI KOCHAKSARAEI G, Castillo E, Osman M, Simmonds K, et al
    Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region.
    J Viral Hepat. 2015 Jul 20. doi: 10.1111/jvh.12436.
    PubMed     Text format     Abstract available


  212. NADKARNI GN, Patel A, Simoes PK, Yacoub R, et al
    Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis.
    J Viral Hepat. 2015 Jul 20. doi: 10.1111/jvh.12437.
    PubMed     Text format     Abstract available


  213. LAWITZ E, Freilich B, Link J, German P, et al
    A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
    J Viral Hepat. 2015 Jul 16. doi: 10.1111/jvh.12435.
    PubMed     Text format     Abstract available


  214. PAPATHEODORIDIS G, Triantos C, Hadziyannis E, Zisimopoulos K, et al
    Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.
    J Viral Hepat. 2015 Jul 6. doi: 10.1111/jvh.12434.
    PubMed     Text format     Abstract available


  215. YU SJ, Kim YJ
    The association between microRNA-323b polymorphism and hepatitis B virus persistent infection - some problems should be addressed.
    J Viral Hepat. 2015;22:626.
    PubMed     Text format    


  216. XU W, Liu J
    The association between microRNA-323b polymorphism and hepatitis B virus persistent infection - some problems should be addressed.
    J Viral Hepat. 2015;22:625.
    PubMed     Text format    


  217. CHOLONGITAS E, Vasiliadis T, Goulis I, Fouzas I, et al
    Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease.
    J Viral Hepat. 2015;22:574-80.
    PubMed     Text format     Abstract available


    June 2015
  218. SARKAR M, Aouzierat B, Bacchetti P, Prokunina-Ollson L, et al
    Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women.
    J Viral Hepat. 2015 Jun 26. doi: 10.1111/jvh.12431.
    PubMed     Text format     Abstract available


  219. CHEN W, Krahn M
    Disease burden of chronic hepatitis C among immigrants in Canada.
    J Viral Hepat. 2015 Jun 25. doi: 10.1111/jvh.12432.
    PubMed     Text format     Abstract available


  220. DOYLE JS, Deterding K, Grebely J, Wedemeyer H, et al
    Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
    J Viral Hepat. 2015 Jun 22. doi: 10.1111/jvh.12429.
    PubMed     Text format     Abstract available


  221. GUTIERREZ JA, Lawitz EJ, Poordad F
    Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
    J Viral Hepat. 2015 Jun 17. doi: 10.1111/jvh.12422.
    PubMed     Text format     Abstract available


  222. HUANG QT, Huang Q, Zhong M, Wei SS, et al
    Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies.
    J Viral Hepat. 2015 Jun 17. doi: 10.1111/jvh.12430.
    PubMed     Text format     Abstract available


  223. WANG Q, Sachse P, Semmo M, Lokhande M, et al
    T- and B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patients.
    J Viral Hepat. 2015 Jun 15. doi: 10.1111/jvh.12428.
    PubMed     Text format     Abstract available


  224. OGAWA E, Furusyo N, Dohmen K, Kajiwara E, et al
    Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    J Viral Hepat. 2015 Jun 15. doi: 10.1111/jvh.12427.
    PubMed     Text format     Abstract available


    May 2015
  225. SETHI N, Tapper EB, Vong A, Sethi S, et al
    Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
    J Viral Hepat. 2015 May 25. doi: 10.1111/jvh.12421.
    PubMed     Text format     Abstract available


  226. GENOWSKA A, Jamiolkowski J, Rodakowska E, Fryc J, et al
    Changing 14-year trends in the epidemiology of hepatitis B virus infection in rural and urban Central-Eastern European areas.
    J Viral Hepat. 2015 May 21. doi: 10.1111/jvh.12420.
    PubMed     Text format     Abstract available


  227. ALAVI M, Micallef M, Fortier E, Dunlop AJ, et al
    Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.
    J Viral Hepat. 2015 May 21. doi: 10.1111/jvh.12415.
    PubMed     Text format     Abstract available


  228. BUTI M, Llaneras J, Riveiro-Barciela M, Esteban R, et al
    Therapy for hepatitis C genotype 3: moving forward.
    J Viral Hepat. 2015 May 13. doi: 10.1111/jvh.12419.
    PubMed     Text format     Abstract available


  229. KIM V, Abreu RM, Nakagawa DM, Baldassare RM, et al
    Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.
    J Viral Hepat. 2015 May 13. doi: 10.1111/jvh.12418.
    PubMed     Text format     Abstract available


  230. ZENG H, Liu H, Wan G, Wang X, et al
    Answer to 'Misdiagnosis of patients may be derived from the interfering factors and used cut-offs in indexes'.
    J Viral Hepat. 2015;22:513-4.
    PubMed     Text format    


  231. COBAN M, Sertoglu E, Kayadibi H
    Misdiagnosis of patients may be derived from the interfering factors and used cut-offs in indexes.
    J Viral Hepat. 2015;22:512.
    PubMed     Text format    


    April 2015
  232. JOHANNESSEN A
    Where we are with point-of-care testing.
    J Viral Hepat. 2015;22:362-5.
    PubMed     Text format     Abstract available


  233. CAREY I, Bruce M, Horner M, Zen Y, et al
    HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.
    J Viral Hepat. 2015;22:441-52.
    PubMed     Text format     Abstract available


    February 2015
  234. AKAMATSU S, Hayes CN, Tsuge M, Murakami E, et al
    Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.
    J Viral Hepat. 2015;22:166-74.
    PubMed     Text format     Abstract available


    January 2015
  235. LEJNINE S, Marton MJ, Wang IM, Howell BJ, et al
    Gene expression analysis in serial liver fine needle aspirates.
    J Viral Hepat. 2015;22:64-76.
    PubMed     Text format     Abstract available


    November 2014
  236. BALTAYIANNIS G, Karayiannis P
    Treatment options beyond IFNalpha and NUCs for chronic HBV infection: expectations for tomorrow.
    J Viral Hepat. 2014;21:753-61.
    PubMed     Text format     Abstract available


    October 2014
  237. MENNA P, Gallo P, Vespasiani Gentilucci U, Salvatorelli E, et al
    Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.
    J Viral Hepat. 2014;21:e136-7.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: